IIM
ACRS icon

INTECH Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

INTECH Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
24,668
+5,472
+29% +$24.4K ﹤0.01% 1893
2026
Q1 		$72K Sell
19,196
-27,450
-59% -$92.6K ﹤0.01% 1957
2025
Q4 		$140K Buy
46,646
+7,702
+20% +$19.5K ﹤0.01% 2090
2025
Q3 		$74K Sell
38,944
-5,787
-13% -$10.1K ﹤0.01% 2324
2025
Q2 		$63.5K Buy
+44,731
New +$60.5K ﹤0.01% 2389

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

INTECH Investment Management's ACRS Position: Q2 2026 in Review

INTECH Investment Management increased its Aclaris Therapeutics (ACRS) stake by 29% in Q2 2026, buying an estimated $24.4K and bringing the position to 24,668 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #1893.

INTECH Investment Management first reported a position in ACRS in Q2 2025 and has held it in 5 quarters since. The position peaked at $140K in Q4 2025. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • INTECH Investment Management held 24,668 shares of Aclaris Therapeutics worth $130K as of Q2 2026.
  • INTECH Investment Management bought 5,472 Aclaris Therapeutics shares in Q2 2026, an estimated $24.4K.
  • Aclaris Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1893 holding.
  • INTECH Investment Management first reported a position in Aclaris Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • INTECH Investment Management's Aclaris Therapeutics position peaked at $140K in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.